Open study of pranlukast add-on therapy in intractable partial epilepsy

Brain & Development
Yukitoshi TakahashiFuminobu Susa

Abstract

Innovative treatments of epileptic seizures are needed to improve the outcome of epilepsy. We studied the effect of pranlukast on seizure outcome in patients with intractable partial epilepsy. An open study was conducted to evaluate the clinical efficacy of 24-week pranlukast add-on therapy in 50 patients with intractable partial seizures. Serum concentrations of matrix metalloproteinase (MMP)-9 were determined using Biotrak Activity Assay System. Cytokines in cerebrospinal fluid (CSF) were measured by the BioPlex (BioRad) system and soluble TNF receptor1 (sTNFR1) in CSF was measured by the ELISA. Surface markers of lymphocytes in CSF were examined by cell-sorter. Seizure-free rate (SFR) was 13.6%, responder rate (RR) was 47.7%, and aggravation rate (AR) was 18.2% at the 13-24 week period after starting pranlukast. In patients with increased serum MMP-9 before pranlukast therapy (baseline), comparison of paired serum levels showed a significant decrease after pranlukast therapy. Baseline CSF levels of IL-1β and IL-6 were elevated in patients compared with disease controls. Of four patients with paired data, three (including a responder to pranlukast) showed decreased pro-inflammatory cytokines (IL-1β, IL-6, and TNFα), and four ...Continue Reading

References

Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·L ProbertG Kollias
Feb 5, 2000·The New England Journal of Medicine·P Kwan, M J Brodie
Jan 19, 2006·Journal of Child Neurology·Salvatore GrossoPaolo Balestri
Feb 24, 2007·Epilepsia·Jacqueline A French
Apr 14, 2007·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·T IchiyamaS Furukawa
May 25, 2007·Epilepsia·Deana M GazzolaJacqueline A French
Mar 8, 2008·Epilepsia·Tore EidNihal C de Lanerolle
Apr 9, 2010·The Keio Journal of Medicine·Masako NozakiTakamura Muraki
Dec 8, 2010·Nature Reviews. Neurology·Annamaria VezzaniTallie Z Baram
Jun 7, 2011·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Ashish K Rehni, Thakur Gurjeet Singh

❮ Previous
Next ❯

Citations

Dec 17, 2014·Seminars in Pediatric Neurology·Joseph J Melvin, H Huntley Hardison
Mar 25, 2016·Expert Review of Neurotherapeutics·Chao DuXuenfeng Wang
Jun 28, 2014·Journal of Immunology Research·A J TheronC Feldman
Mar 25, 2015·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Betul CevikOytun Erbas
Feb 17, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Juliana FleckCarlos Fernando Mello
Feb 26, 2016·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J FleckC F Mello
Dec 8, 2019·International Journal of Molecular Sciences·Keith A Kwan CheungMurray D Mitchell
Jun 14, 2017·Mediators of Inflammation·Paolo GelosaLaura Castiglioni
Jan 29, 2021·Journal of Experimental Pharmacology·Bekalu Amare TesfayeDerbew Fikadu Berhe
Jun 8, 2021·Frontiers in Psychiatry·Keith A Kwan CheungHelen S Heussler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Acute Hemorrhagic Leukoencephalitis

Acute hemorrhagic leukoencephalitis is a rare form of acute disseminated encephalomyelitis characterized by acute inflammation in the brain and spinal cord that causes demyelination and bleeding. It is often fatal, although treatment with immunosuppressives and plasma exchange can be helpful. Find the latest research on acute hemorrhagic leukoencephalitis here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.